Voltadol 140mg 5 Medicated Patches
- Brand:GLAXOSMITHKLINE C.HEALTH.Srl
- Product Code: 035520016
- Availability: In Stock
- Purchase 3 items for 8.42€ each
- Purchase 4 items for 8.25€ each
- Purchase 5 items for 8.07€ each
Voltadol Patches is used in the local treatment of painful and inflammatory rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.
Dosage and mode of use
Voltadol Patches is used according to the following particulars, unless otherwise prescribed: the product should be applied only to intact skin and healthy and should not be applied when you bathe or shower.
The medicated plaster of diclofenac must be used for the shortest possible time in relation to the indication of use.
- Adults and adolescents aged 16 years and over: unless otherwise prescribed apply a patch 2 times a day, morning and evening, on the skin of the treated area for a period of not more than 7-10 days.
If you do not see an improvement following the recommended treatment period, you will have to consult a doctor. Adolescents aged over 16 years, if that product is required for a period longer than 7 days of treatment for the relief of pain, or if symptoms worsen, it is recommended to the patient or to the adolescent's family to seek medical advice .
- Hypersensitivity 'to the active substance or to any of the excipients or to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs, as well as' the isopropanol.
- Pregnancy and breast-feeding should not be administered in case of pregnancy and during lactation.
The possibility of systemic adverse events with the application of topical diclofenac can not be excluded if the preparation is used on large areas and skin for an extended period (see the summary of product characteristics of the systemic forms of diclofenac).
Topical Diclofenac should only be applied to intact skin, not sick, not on skin wounds or open injuries. It should not be left to get in touch with the eyes or mucous membranes and should not be ingested. Topical diclofenac can be used with non-occlusive bandages but should not be used with occlusive dressings that do not let air pass.
Itamideve be used with caution in patients who have previously had a hypersensitivity reaction to NSAIDs and analgesics, eg. asthma attacks, rashes
skin, allergic rhinitis and acute anaphylactoid reactions. Asthma patients with obstructive chronic diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyps) reacting with asthma, local inflammation of the skin or mucosal attacks (Quincke's edema) or hives to treatment with more often than other NSAIDs patients.
The administration of Itamidovrebbe be discontinued in women who have fertility problems or undergoing fertility tests. The use, especially if prolonged, of products for topical use may give rise to sensitization phenomena. Discontinue treatment if skin rash develops after applying the product and consult your doctor for the establishment of appropriate therapy. After a short period of treatment with no significant results, consult the
Although systemic absorption is minimal, however the use of ITAMI, like any medication inhibitor of prostaglandin synthesis and cyclooxygenase is not recommended in women attempting to become pregnant. Keep this medicine out of the reach and sight of children.
Pregnancy and breastfeeding
The systemic concentration of diclofenac, compared with oral formulations, is lower after topical administration. Drawing on experience with NSAID treatment for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and / or the embryo / fetus. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformations increased from less than 1%, up to about 1.5%.
E 'was found that the risk increases with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to
result in an increase in loss of pre- and post-implantation and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals whose synthesis prostaglandin inhibitors were administered during the organogenesis period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of the shortest possible treatment.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:
- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction, which may progress to renal failure with oligoidroamnios;
The mother and the neonate, at the end of pregnancy, may be exposed to:
- possible prolongation of bleeding time, and antiplatelet effect which may occur even at very low doses;
- inhibition of uterine contractions resulting in delayed or prolonged labor.
Consequently, diclofenac is contraindicated during the third trimester of pregnancy.
Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of Itaminon are expected effects on the nursing infant. Because of the lack of controlled studies in lactating women, the product should be used during breastfeeding only on the advice of a health professional. In this circumstance, Itaminon must be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for an extended period of time
Shelf life and storage
Check the expiration date on the package. The expiration date on the package refers to the sealed container when stored. Store in the original package to protect from moisture.
Caution: Do not use the medicine after the expiration date on the package.
Voltadol Patch contains:
Active ingredient: diclofenac sodium 140 mg
Excipients: Butyl methacrylate copolymer basic; acrylate-vinyl acetate copolymer; polyethylene glycol 12 stearate; sorbitan oleate; Non-woven fabric; silicone paper.